Race CEO Dr Daniel Tillett spoke with Johnathan Jackson at Proactive about the completion of GLP studies for RC220 bisantrene.

Dr Tillett noted that the studies demonstrated excellent safety profile for RC220 bisantrene. It gives the new formulation of bisantrene IP and protection, moves the drug closer to human clinical trial, and marks a starting dose for the upcoming Phase 1 trial.

Read the full article here.